WHERE ARE YOU?

Concept Pre-Sub Submission prep Newly cleared Raising Exit Postmarket & security

THE TAPE

Comments close on FDA's generative AI device framework Solventum clears its Restrata matrix for use under V.A.C. negative pressure therapy Medtronic takes a CE mark for five conduction system pacing pacemakers Paradromics hands Siemens Healthineers the imaging workup for its brain implant Empyrean submits a 510(k) for Vektra, its robotic brachytherapy system Masimo clears AFib detection on the Radius VSM wearable monitor Sequel clears the twiist insulin pump for adults with type 2 diabetes FTC issues a second request on the MiMedx purchase of Sanara MedTech Labcorp pays $722M upfront for BioReference testing assets Comments close on FDA's generative AI device framework Solventum clears its Restrata matrix for use under V.A.C. negative pressure therapy Medtronic takes a CE mark for five conduction system pacing pacemakers Paradromics hands Siemens Healthineers the imaging workup for its brain implant Empyrean submits a 510(k) for Vektra, its robotic brachytherapy system Masimo clears AFib detection on the Radius VSM wearable monitor Sequel clears the twiist insulin pump for adults with type 2 diabetes FTC issues a second request on the MiMedx purchase of Sanara MedTech Labcorp pays $722M upfront for BioReference testing assets

FDA Docket

Comments close on FDA's generative AI device framework

MedDevice Startups Staff · 2 days ago · 2 min read · Via FDA press announcement

The comment period on FDA's generative AI device framework closed October 19. The agency's discussion paper, "Considerations for the Regulation of Generative AI-Enabled Medical Devices," sits in docket FDA-2026-N-7874 and came out of CDRH's Digital Health Center of Excellence on August 18.

The paper proposes a two-axis risk assessment framework and a premarket approach built on competency assessment: non-clinical benchmarking of the device, then clinical confirmation before it reaches patients. It also lays out several options for risk-proportionate postmarket monitoring, and it addresses foundation models and agentic systems directly.

None of it binds anyone yet. This is a discussion paper, not draft guidance, and FDA says it is still working through the approaches. For a company with a generative model inside its product, the comments filed by October 19 are the record FDA will draw on when it writes guidance, and the competency assessment language is the part worth reading twice.

Questions & Answers

What is FDA docket FDA-2026-N-7874 about?

Docket FDA-2026-N-7874 holds FDA's discussion paper "Considerations for the Regulation of Generative AI-Enabled Medical Devices," issued August 18, 2026 by CDRH's Digital Health Center of Excellence. The comment period on it closed October 19, 2026.

What premarket approach does FDA's generative AI discussion paper propose?

The FDA discussion paper proposes a premarket approach based on competency assessment: non-clinical benchmarking of the generative AI device, followed by clinical confirmation before the device reaches patients. It pairs that with a two-axis risk assessment framework.

Does the FDA generative AI discussion paper create new requirements for device makers?

No. The August 2026 paper is a discussion document, not draft or final guidance, so it imposes no new requirements. FDA says it is still exploring the approaches described, and the comments filed by the October 19, 2026 deadline will inform any future guidance.

← Back to Regulatory